NEW YORK–(BUSINESS WIRE)– Koneksa, a healthcare technology company pioneering evidence-based digitalbiomarkers, announced today the appointment of Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthibrings over 25 years of experience in life sciences and will lead corporate and business development initiatives atKoneksa.
“We’re thrilled to welcome Eric to lead our business development team,” said Chris Benko, CEO and Co-Founder ofKoneksa. “With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotalrole in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. Hisleadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trialsand unlock critical data insights.”
“I’m honored to join Koneksa as we continue to advance the role of evidence-based digital biomarkers in clinical trials toaccelerate decision making and improve patient outcomes,” said Eric Luthi, Chief Business Officer, Koneksa. “Ourcommitment to leveraging advanced technology and real-time data streaming for data-driven insights is unparalleled. Ourrecent data syndication efforts encourage pre-competitive collaboration among companies to validate novel digitalendpoints to provide baseline disease metrics in Parkinson’s disease. This approach not only benefits our partners butalso supports improved patient outcomes. I’m excited to expand these partnerships and drive similar initiatives acrossadditional therapeutic areas.”
Prior to joining Koneksa, Mr. Luthi served as Chief Commercial Officer at Evergreen Therapeutics, where he establishedthe commercial function and led the development of the launch strategy for the company’s diagnostic radiopharmaceutical.
Eric has held commercial leadership roles in large and small pharmaceutical companies in the US, Canada, andSwitzerland. Over his 20-year tenure at Merck & Co., Inc., Eric helped to integrate research and commercial strategies in anumber of key therapeutic areas for the company and, working closely with R&D leadership, was the commercial lead forcardiovascular products in clinical development. As head of Digital and Commercial Operations for Merck’s subsidiary inCanada, he was responsible for enhancing customer engagement and driving revenue growth by integrating digital andtraditional marketing efforts. He holds a Bachelor of Science degree with a double major in Biology and Psychology fromMuhlenberg College.
About Koneksa
Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical researchand guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enableefficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatmenteffect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.
Media
Kimberly Ha
KKH Advisors9
17-291-5744
kimberly.ha@kkhadvisors.com